Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

EDP-322

Small molecule · developed by Enanta Pharmaceuticals

Phase 1 Most advanced trial (none active)
ENTA Developer
1 Registered trials

What is EDP-322?

EDP-322 is a drug studied in methicillin-resistant Staphylococcus aureus (MRSA) and skin and skin structure infections (SSTI).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Dermatology, Infectious disease
Developer
Enanta Pharmaceuticals, Inc (ENTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00990145 Phase 1 MRSA, SSTI Completed ENTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MRSA, SSTI

More from Enanta Pharmaceuticals

EDP-235 Phase 2 EDP-297 Phase 1 EDP-305 Phase 2 EDP-323 Phase 2 EDP-494 Phase 1 EDP-514 Phase 1 EDP-721 Phase 1 EDP-788 Phase 1 EDP-978 Phase 1 EDP239 Phase 1 Zelicapavir Phase 2

Follow ENTA, the company behind EDP-322

See ENTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.